Navigation Links
Genzyme Files Applications for Approval of Mozobil in the United States and Europe
Date:6/17/2008

hese statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward- looking statements. These risks and uncertainties include, among others, the failure to receive regulatory approval to commercialize Mozobil in the U.S., Europe or other countries, the lack of adoption of the product in other therapeutic areas, the inability to change current treatment protocols and risks associated with commercial launch and the risks and uncertainties described in reports filed by Genzyme with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended, including without limitation the information under the heading "Risk Factors" in the Management's Discussion and Analysis of Financial Condition and Results of Operations section of the Genzyme Quarterly Report on Form 10-Q for the quarter ending March 31, 2008. Genzyme cautions investors not to place substantial reliance on the forward-looking statements contained in this press release. These statements speak only as of the date of this press release, and Genzyme undertakes no obligation to update or revise the statements.

Genzyme's press releases and other company information are available at http://www.genzyme.com and by calling Genzyme's investor information line at 1-800- 905-4369 within the United States or 1-678-999-4572 outside the United States.

Media Contact:

Bo Piela

(617) 768-6579

Investor Contact:

Patrick Flanigan

(617) 768-6563


'/>"/>
SOURCE Genzyme Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Genzyme Boosts Quality Using Dyadem Quality Lifecycle Management
2. Awareness of Genzymes Renvela(R) (Sevelamer Carbonate) is High, Although Uptake of this New Phosphate Binding Agent has Been Slower than Nephrologists and Renal Dietitians Initially Expected
3. Genzyme Reports Strong First-Quarter Growth
4. Genzyme to Build New R&D Center in Beijing
5. Genzyme Provides Update on Myozyme(R) Manufacturing
6. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
7. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
8. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
9. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
10. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
11. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... Md. , Sept. 15, 2014   ... leading innovator of scientific products and services for ... One Acquisition Solution for Integrated Services (OASIS) from ... (FAS). GST was selected to provide the government ... the Small Business (SB) category in Pool 4. ...
(Date:9/15/2014)... fast when a patient has sepsis, a life-threatening condition ... blood -- often too fast for antibiotics to help. ... developed by a team at Harvard,s Wyss Institute for ... treat sepsis. , "Even with the best current ... at least 30 percent of the time," said Mike ...
(Date:9/15/2014)... , Sept. 15, 2014  iVinci Health LLC, the ... Patient Revenue Management system, branded as VisitPay®, has successfully ... announced the launch of a new extension to VisitPay® ... an easy and convenient way for patients to manage ... owed by them and their families. The ...
(Date:9/15/2014)... , 15 septembre 2014 La ... Week (IPAW) (semaine internationale sur la sensibilisation ... octobre. Initiative conjointe de la Plasma Protein ... sociétés membres , l,IPAW vise à : ... sujet de la collecte du plasma-aphérèse , ...
Breaking Biology Technology:Global Science & Technology, Inc. Awarded GSA OASIS Small Business Contract 2Global Science & Technology, Inc. Awarded GSA OASIS Small Business Contract 3Blood-cleansing biospleen device developed for sepsis therapy 2Blood-cleansing biospleen device developed for sepsis therapy 3Blood-cleansing biospleen device developed for sepsis therapy 4iVinci Health Raises $5M to Fuel National Expansion, Announces Launch of Personal Finance Portal for Healthcare 2iVinci Health Raises $5M to Fuel National Expansion, Announces Launch of Personal Finance Portal for Healthcare 3L' International Plasma Awareness Week célébrera les donneurs et braquera les projecteurs sur les maladies rares 2L' International Plasma Awareness Week célébrera les donneurs et braquera les projecteurs sur les maladies rares 3
... 11:26 a.m. EDT, the space shuttle Atlantis will streak skyward ... last mission. While the STS-135 flight marks the end of ... a new era of research into infectious diseases, thanks to ... Curtiss III, along with their colleagues at Arizona State University,s ...
... 2011 By applying a coating to individual silicon ... the materials, efficiency and sensitivity. The findings, published ... Letters , suggest that the coated wires hold promise ... Due to a large surface-to-volume ratio, nanowires typically ...
... Phalanx Biotech Group, a global provider of genomic ... expression microarray family – the Rice Genome OneArray®. ... to meet specific isothermal requirements for superb hybridization ... and demonstrates high correlation with qPCR. As opposed ...
Cached Biology Technology:Final countdown: Atlantis to carry next-generation vaccine candidate on last space voyage 2Final countdown: Atlantis to carry next-generation vaccine candidate on last space voyage 3Final countdown: Atlantis to carry next-generation vaccine candidate on last space voyage 4With a simple coating, nanowires show a dramatic increase in efficiency and sensitivity 2Phalanx Biotech Group Launches Rice Genome OneArray® 2
(Date:9/15/2014)... from digestion to disease resistance. Despite the fact that ... the planet, more is known about belly-button bacteria than ... colleagues working on Panama,s Barro Colorado Island discovered that ... to more than 400 different kinds of bacteria. The ... 7,000 different kinds. , Bacteria in tropical forests may ...
(Date:9/15/2014)... CAMBRIDGE, Mass. (September 15, 2014) The so-called ... which makes proteinhas long provided a simplified explanation ... in living organisms. , In reality, of ... the schema first articulated nearly 60 years ago ... DNA,s double-helix structure. For one, there are multiple ...
(Date:9/15/2014)... lowland tapir populations may continue to drop in French ... the Office National de la Chasse et de la ... Global reviewed data retrieved from camera traps in the ... compared this data to current harvest rates in the ... in French Guiana," said Matthias Tobler, a scientist with ...
Breaking Biology News(10 mins):Smithsonian scientists discover tropical tree microbiome in Panama 2Scientists discover RNA modifications in some unexpected places 2
... and fertilizer technology used around the world today were ... scientists and engineers at the Tennessee Valley Authority (TVA) ... TVA official. Shields is now Interim Director of IFDC, ... based in Muscle Shoals, Alabama. "An investment ...
... bizarre qualities that improve a creature,s chances of ... separation of populations and the evolution of new ... In the September 2008 issue of Evolution ... examine males from four geographically separated populations of ...
... Davis M.I.N.D. Institute and The Children,s Hospital in Denver have ... psychological characteristics of a rare genetic disorder in which males ... normal one of each. The study, published in the June ... Genetics Part A, also offers treatment recommendations for men ...
Cached Biology News:TVA fertilizer technology used worldwide -- but few new products since 1970s 2TVA fertilizer technology used worldwide -- but few new products since 1970s 3TVA fertilizer technology used worldwide -- but few new products since 1970s 4How 'secondary' sex characters can drive the origin of species 2How 'secondary' sex characters can drive the origin of species 3UC Davis researchers define characteristics, treatment options for XXYY syndrome 2UC Davis researchers define characteristics, treatment options for XXYY syndrome 3
Goat anti-VAV2 Class: Antibody Product Group: Miscellaneous Antibody...
... Mouse monoclonal [F30 P7 D7 ... for all tested applications). ... conjugated to Ovalbumin, corresponding to amino ... Entrez Gene ID: ...
DAP12 Market Segment: Protein Kinases...
G-protein coupled purinergic receptor P2Y8...
Biology Products: